Biocon News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Biocon Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 1
Author: ICICI Direct

Keep track of all breaking news and updates on Biocon from all sources in a single place.

Biocon Ltd.

13 Dec 2025

386.35

1.20%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Biocon Ltd.

11 Dec 2025, 01:22PM

386.35

1.20%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Biocon Ltd.

10 Dec 2025

386.35

1.20%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)

pdf

Biocon Ltd.

10 Dec 2025

386.35

1.20%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation regarding Credit Rating

pdf

Biocon Ltd.

10 Dec 2025

386.35

1.20%

Biocon Ltd.

Sell: Biocon Ltd.

Recommendation Target

ICICI Direct

announced to acquire entire minority shareholder stake of 23.3% in Biocon Biologics held by Viatris (Mylan Inc.), Serum Institute, True North and Tata Capital for US$ 1.173 billion, making it a wholly-owned subsidiary and valuing BBL at US$ 5.5 billion. Biocon will issue its shares worth US$ 773 million and make a cash payment to Viatris for the balance US$ 400 million. Cash payment to be paid by bridge / interim funding and a...

Biocon Ltd. has an average target of 376.40 from 5 brokers.

Biocon Ltd.

09 Dec 2025

386.35

1.20%

Investor Presentation

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor Presentation

pdf

Biocon Ltd.

08 Dec 2025

386.35

1.20%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication

pdf

Biocon Ltd.

08 Dec 2025

386.35

1.20%

Integration to bring scale and clarity

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) is fully integrating Biocon Biologics (BBL) by acquiring the remaining stake of 23.3%. In addition to the share swap, BIOS is raising additional capital through a QIP of up to INR45b, subject to shareholder approval, for the cash component payable to Viatris.